BioCentury | Nov 24, 2020
Management Tracks

ASCO names Gralow new CMO; plus moves at Genenta, Vor, Exscientia, OncoMyx, Quanterix, Actinium, AbCellera and KBP

...to its board. KBP Biosciences Co. Ltd. named Douglas Losordo CMO. Losordo  joins the company from Caladrius Biosciences Inc....
BioCentury | Aug 22, 2020
Emerging Company Profile

Luminary: turning cell engineering tools into therapies

...the CDMO unit of cell therapy company Caladrius Biosciences Inc....
BioCentury | Aug 11, 2020
Emerging Company Profile

GentiBio: combining trio of platforms to enhance Treg therapies

...editing company Intellia Therapeutics Inc. (NASDAQ:NTLA) and Caladrius Biosciences Inc....
BioCentury | Mar 22, 2019
Product Development

Regulating regeneration in Europe

...it, “after just an initial suggestion of efficacy and a read for safety,” said Stapleton. Caladrius Biosciences Inc.’s...
...clinical trial data. EMA has not issued any updates since 2016. Companies and Institutions Mentioned Caladrius Biosciences Inc....
...Food and Drug Administration (FDA), Silver Spring, Md. Zelluna Immunotherapy A/S, Oslo, Norway Lauren Martz, Associate Editor Caladrius Biosciences Inc. Celixir...
BioCentury | Mar 23, 2018
Clinical News

Caladrius reports interim Phase II data for Type I diabetes candidate

...product has Orphan Drug and Fast Track designations for Type I diabetes in the U.S. Caladrius Biosciences Inc....
...episodes and safety Status: Interim Phase II data Milestone: Additional Phase II data (early 2019) Sandi Wong CLBS03 Caladrius Biosciences Inc....
BioCentury | Mar 9, 2018
Company News

Caladrius gets late-stage cell therapy from Shire

...Shire plc (LSE:SHP; NASDAQ:SHPG) granted Caladrius Biosciences Inc. (NASDAQ:CLBS) an exclusive, worldwide license to data and regulatory filings...
...plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Caladrius Biosciences Inc. (NASDAQ:CLBS), Basking Ridge, N.J. Business: Cardiovascular Elizabeth S. Eaton Baxter International Inc. Caladrius Biosciences Inc. Shire...
BioCentury | Sep 29, 2017
Company News

Casebia, Seattle Children's partner to develop gene-edited Tregs

...companies pursuing ways of selectively enhancing Treg activity in autoimmune diseases include Delinia Inc. , Caladrius Biosciences Inc....
...Xetra:BAYN), Leverkusen, Germany Seattle Children's Research Institute , Seattle, Wash. Business: Gene/Cell therapy, Autoimmune Mary Romeo Bayer AG Caladrius Biosciences Inc. Celgene...
BioCentury | Sep 27, 2017
Company News

Casebia, Seattle Children's partner to develop gene-edited Tregs

...Other companies pursuing ways of selectively enhancing Treg activity in autoimmune diseases include Delinia Inc., Caladrius Biosciences Inc....
...Corp. (NASDAQ:CELG) acquired Delinia earlier this year (see BioCentury Innovations, Oct. 13, 2016) . Mary Romeo Bayer AG Caladrius Biosciences Inc. Celgene...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

...from self-renewing, proliferating autologous tumor cells in GM-CSF Acquired in 2014 by NeoStem Inc. (now Caladrius Biosciences Inc....
BioCentury | Mar 10, 2017
Company News

CIRM funding news

...of AlloJoin for the indication. The product is an allogeneic adipose-derived mesenchymal progenitor cell therapy. Caladrius Biosciences Inc....
...Angeles, Calif. St. Jude Children's Research Hospital , Memphis, Tenn. Business: Gene/Cell therapy, Endocrine/Metabolic, Neurology Chris Lieu CLBS03 Caladrius Biosciences Inc. California...
Items per page:
1 - 10 of 121
BioCentury | Nov 24, 2020
Management Tracks

ASCO names Gralow new CMO; plus moves at Genenta, Vor, Exscientia, OncoMyx, Quanterix, Actinium, AbCellera and KBP

...to its board. KBP Biosciences Co. Ltd. named Douglas Losordo CMO. Losordo  joins the company from Caladrius Biosciences Inc....
BioCentury | Aug 22, 2020
Emerging Company Profile

Luminary: turning cell engineering tools into therapies

...the CDMO unit of cell therapy company Caladrius Biosciences Inc....
BioCentury | Aug 11, 2020
Emerging Company Profile

GentiBio: combining trio of platforms to enhance Treg therapies

...editing company Intellia Therapeutics Inc. (NASDAQ:NTLA) and Caladrius Biosciences Inc....
BioCentury | Mar 22, 2019
Product Development

Regulating regeneration in Europe

...it, “after just an initial suggestion of efficacy and a read for safety,” said Stapleton. Caladrius Biosciences Inc.’s...
...clinical trial data. EMA has not issued any updates since 2016. Companies and Institutions Mentioned Caladrius Biosciences Inc....
...Food and Drug Administration (FDA), Silver Spring, Md. Zelluna Immunotherapy A/S, Oslo, Norway Lauren Martz, Associate Editor Caladrius Biosciences Inc. Celixir...
BioCentury | Mar 23, 2018
Clinical News

Caladrius reports interim Phase II data for Type I diabetes candidate

...product has Orphan Drug and Fast Track designations for Type I diabetes in the U.S. Caladrius Biosciences Inc....
...episodes and safety Status: Interim Phase II data Milestone: Additional Phase II data (early 2019) Sandi Wong CLBS03 Caladrius Biosciences Inc....
BioCentury | Mar 9, 2018
Company News

Caladrius gets late-stage cell therapy from Shire

...Shire plc (LSE:SHP; NASDAQ:SHPG) granted Caladrius Biosciences Inc. (NASDAQ:CLBS) an exclusive, worldwide license to data and regulatory filings...
...plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Caladrius Biosciences Inc. (NASDAQ:CLBS), Basking Ridge, N.J. Business: Cardiovascular Elizabeth S. Eaton Baxter International Inc. Caladrius Biosciences Inc. Shire...
BioCentury | Sep 29, 2017
Company News

Casebia, Seattle Children's partner to develop gene-edited Tregs

...companies pursuing ways of selectively enhancing Treg activity in autoimmune diseases include Delinia Inc. , Caladrius Biosciences Inc....
...Xetra:BAYN), Leverkusen, Germany Seattle Children's Research Institute , Seattle, Wash. Business: Gene/Cell therapy, Autoimmune Mary Romeo Bayer AG Caladrius Biosciences Inc. Celgene...
BioCentury | Sep 27, 2017
Company News

Casebia, Seattle Children's partner to develop gene-edited Tregs

...Other companies pursuing ways of selectively enhancing Treg activity in autoimmune diseases include Delinia Inc., Caladrius Biosciences Inc....
...Corp. (NASDAQ:CELG) acquired Delinia earlier this year (see BioCentury Innovations, Oct. 13, 2016) . Mary Romeo Bayer AG Caladrius Biosciences Inc. Celgene...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

...from self-renewing, proliferating autologous tumor cells in GM-CSF Acquired in 2014 by NeoStem Inc. (now Caladrius Biosciences Inc....
BioCentury | Mar 10, 2017
Company News

CIRM funding news

...of AlloJoin for the indication. The product is an allogeneic adipose-derived mesenchymal progenitor cell therapy. Caladrius Biosciences Inc....
...Angeles, Calif. St. Jude Children's Research Hospital , Memphis, Tenn. Business: Gene/Cell therapy, Endocrine/Metabolic, Neurology Chris Lieu CLBS03 Caladrius Biosciences Inc. California...
Items per page:
1 - 10 of 121